The GnRH agonists have the same MOA as the antagonists after an initial treatment period. I think the FDA is going to want to see a lot of long-term studies from Neurocrine that they have not run and don't have the money to run. I would take this spike in the price as an opportunity to get out of the stock.
Market Data 
Markets 
AI
